Jun 2026 (Q2 FY26) — Aug 5, 2026
Kymera Therapeutics Q2 FY26 — Accelerated KT-621 AD Enrollment and Pipeline Advancement
Read the full callKymera Therapeutics (KYMR) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Kymera Therapeutics earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 65.0 | +466.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -116.3 | +620.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -61.2 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$108.07 +3.14% · +$3.29
Performance +80.6% 1Y
1Y: $59.83 on 17 Oct 2025 → $108.07. High $127.31 (19 Aug 2026), low $55.8 (22 Oct 2025).
- Previous close
- $104.78
- 52-week range
- $55.8 – $127.31
- One year
- +78.63%
Overview
- Symbol
- KYMR
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q1 FY26) — Apr 30, 2026
Kymera Therapeutics Q1 FY26 — Pipeline Advancement and Strong Financial Position
Read the full callDec 2025 (Q4 FY25) — Feb 26, 2026
Kymera Therapeutics Q4 FY25 — Strong Pipeline Progress and Extended Cash Runway
Read the full callEvery analysed call
Kymera Therapeutics earnings calls (KYMR)
Financials
What the filings say
Net profit, year on year: +20% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 4 | 7 | 22 | 11 | 3 | 3 | 34 | 65 |
| Operating profit | -72 | -81 | -74 | -85 | -93 | -98 | -84 | -76 |
| Operating margin | −1927.9% | −1092.2% | −336.8% | −736.8% | −3347.4% | −3409.8% | −244.9% | −116.3% |
| Net profit | -62 | -71 | -66 | -77 | -82 | -87 | -69 | -61 |
| EPS ($ per share) | -0.82 | — | -0.82 | -0.95 | -0.94 | — | -0.71 | -0.62 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Equity capital | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -76 | -129 | -229 | -384 | -531 | -755 | -1,066 |
| Total liabilities | 82 | 203 | 146 | 113 | 181 | 142 | 163 |
| Fixed assets | 4 | 11 | 12 | 13 | 48 | 50 | 43 |
| Total assets | 117 | 487 | 606 | 603 | 576 | 978 | 1,743 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | 18 | 88 | -129 | -153 | -103 | -195 | -233 |
| Cash from investing | -16 | -423 | -100 | 21 | 140 | -404 | -521 |
| Cash from financing | 35 | 289 | 250 | 153 | 4 | 609 | 991 |
| Net cash flow | 36 | -45 | 21 | 20 | 41 | 10 | 237 |
| Capital expenditure | -1 | -9 | -2 | -3 | -34 | -13 | -1 |
| Free cash flow | 17 | 79 | -131 | -156 | -137 | -207 | -234 |
Insider filings
315 filings between Oct 29, 2025 and Oct 1, 2026.
Open market
decisions to buy or sellPurchases
$172.50M
2 purchases by 1 insider
Sales
$466.83M
263 sales by 11 insiders
84% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 6
- Award — granted as compensation
- 44
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Booth Bruce | — | $217.75M | Jun 29, 2026 |
| BVF PARTNERS L P/IL | — | $173.67M | Jun 26, 2026 |
| BAKER BROS. ADVISORS LP | $172.50M | — | Dec 11, 2025 |
| Mainolfi Nello | — | $36.82M | Oct 1, 2026 |
| Chadwick Jeremy G | — | $15.60M | May 27, 2026 |
| Jacobs Bruce N. | — | $9.96M | Jun 30, 2026 |
| Gollob Jared | — | $5.29M | Mar 4, 2026 |
| Esposito Pamela | — | $3.05M | Mar 20, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Mainolfi Nello Chief Executive Officer | Sale 10b5-1 plan | 5,506 | $619.0K |
| Oct 1, 2026 | Mainolfi Nello Chief Executive Officer | Sale 10b5-1 plan | 3,525 | $392.8K |
| Oct 1, 2026 | Mainolfi Nello Chief Executive Officer | Sale 10b5-1 plan | 7,601 | $869.8K |
| Oct 1, 2026 | Mainolfi Nello Chief Executive Officer | Sale 10b5-1 plan | 8,230 | $949.7K |
| Oct 1, 2026 | Mainolfi Nello Chief Executive Officer | Sale 10b5-1 plan | 4,876 | $552.2K |
| Oct 1, 2026 | Mainolfi Nello Chief Executive Officer | Option exercise 10b5-1 plan | 30,000 | $62.4K |
| Oct 1, 2026 | Mainolfi Nello Chief Executive Officer | Sale 10b5-1 plan | 262 | $30.4K |
| Sep 4, 2026 | Adams Brian Chief Legal Officer | Sale | 2,137 | $251.2K |
| Sep 4, 2026 | Adams Brian Chief Legal Officer | Sale | 3,025 | $353.4K |
| Sep 4, 2026 | Adams Brian Chief Legal Officer | Sale | 1,209 | $139.7K |
| Jul 27, 2026 | Rooney Terence Chief Medical Officer | Award | 38,000 | $0 |
| Jul 7, 2026 | Mainolfi Nello Chief Executive Officer | Sale 10b5-1 plan | 50,000 | $5.95M |
| Jul 7, 2026 | Mainolfi Nello Chief Executive Officer | Option exercise 10b5-1 plan | 50,000 | $104.0K |
| Jul 1, 2026 | Mainolfi Nello Chief Executive Officer | Sale 10b5-1 plan | 24,105 | $2.77M |
| Jul 1, 2026 | Mainolfi Nello Chief Executive Officer | Sale 10b5-1 plan | 6,626 | $755.2K |
| Jul 1, 2026 | Mainolfi Nello Chief Executive Officer | Sale 10b5-1 plan | 1,883 | $212.4K |
| Jul 1, 2026 | Mainolfi Nello Chief Executive Officer | Sale 10b5-1 plan | 3,336 | $388.8K |
| Jul 1, 2026 | Mainolfi Nello Chief Executive Officer | Sale 10b5-1 plan | 44,050 | $5.10M |
| Jul 1, 2026 | Mainolfi Nello Chief Executive Officer | Option exercise 10b5-1 plan | 80,000 | $166.4K |
| Jul 1, 2026 | Goodman Noah Chief Business Officer | Sale 10b5-1 plan | 3,389 | $387.3K |
| Jun 30, 2026 | Jacobs Bruce N. Chief Financial Officer | Sale 10b5-1 plan | 4,110 | $469.3K |
| Jun 30, 2026 | Jacobs Bruce N. Chief Financial Officer | Sale 10b5-1 plan | 1,100 | $124.1K |
| Jun 30, 2026 | Jacobs Bruce N. Chief Financial Officer | Option exercise 10b5-1 plan | 61,378 | $327.1K |
| Jun 30, 2026 | Jacobs Bruce N. Chief Financial Officer | Sale 10b5-1 plan | 1,700 | $189.7K |
| Jun 30, 2026 | Jacobs Bruce N. Chief Financial Officer | Sale 10b5-1 plan | 51,375 | $5.90M |
| Jun 30, 2026 | Jacobs Bruce N. Chief Financial Officer | Sale 10b5-1 plan | 1,500 | $165.8K |
| Jun 30, 2026 | Jacobs Bruce N. Chief Financial Officer | Sale 10b5-1 plan | 3,200 | $376.6K |
| Jun 30, 2026 | Jacobs Bruce N. Chief Financial Officer | Sale 10b5-1 plan | 6,153 | $719.9K |
| Jun 30, 2026 | Jacobs Bruce N. Chief Financial Officer | Sale 10b5-1 plan | 7,971 | $923.2K |
| Jun 29, 2026 | Booth Bruce Director | Sale 10b5-1 plan | 1,104 | $121.2K |
| Jun 29, 2026 | Booth Bruce Director | Sale 10b5-1 plan | 1,498 | $162.2K |
| Jun 29, 2026 | Booth Bruce Director | Sale 10b5-1 plan | 2,698 | $290.7K |
| Jun 29, 2026 | Booth Bruce Director | Sale 10b5-1 plan | 2,133 | $227.4K |
| Jun 29, 2026 | Booth Bruce Director | Sale 10b5-1 plan | 770 | $81.5K |
| Jun 29, 2026 | Booth Bruce Director | Sale 10b5-1 plan | 934 | $103.9K |
| Jun 29, 2026 | Booth Bruce Director | Sale 10b5-1 plan | 7,968 | $874.5K |
| Jun 29, 2026 | Booth Bruce Director | Sale 10b5-1 plan | 7,723 | $854.7K |
| Jun 29, 2026 | Booth Bruce Director | Sale 10b5-1 plan | 10,848 | $1.17M |
| Jun 29, 2026 | Booth Bruce Director | Sale 10b5-1 plan | 19,419 | $2.09M |
| Jun 29, 2026 | Booth Bruce Director | Sale 10b5-1 plan | 5,549 | $587.0K |
| Jun 29, 2026 | Booth Bruce Director | Sale 10b5-1 plan | 130 | $14.5K |
| Jun 29, 2026 | Booth Bruce Director | Sale 10b5-1 plan | 1,078 | $119.3K |
| Jun 29, 2026 | Booth Bruce Director | Sale 10b5-1 plan | 14,798 | $1.58M |
| Jun 26, 2026 | Booth Bruce Director | Sale 10b5-1 plan | 1,442 | $160.8K |
| Jun 26, 2026 | Booth Bruce Director | Sale 10b5-1 plan | 1,579 | $174.5K |
| Jun 26, 2026 | Booth Bruce Director | Sale 10b5-1 plan | 4,562 | $500.9K |
| Jun 26, 2026 | Booth Bruce Director | Sale 10b5-1 plan | 32,402 | $3.50M |
| Jun 26, 2026 | Booth Bruce Director | Sale 10b5-1 plan | 3,958 | $425.8K |
| Jun 26, 2026 | Booth Bruce Director | Sale 10b5-1 plan | 12,390 | $1.47M |
| Jun 26, 2026 | Booth Bruce Director | Sale 10b5-1 plan | 22,046 | $2.60M |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Kymera Therapeutics, Inc.
Free account. Everything above stays public.
Write why you follow Kymera Therapeutics, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading